How do you horizontal ellipsis decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?

被引:4
|
作者
Lu, Wen [1 ]
Delaney, Meghan [2 ]
Flegel, Willy A. [3 ]
Ness, Paul [4 ]
Ratcliffe, Nora [5 ]
Triulzi, Darrell J. [6 ]
Yazer, Mark H. [6 ]
Ziman, Alyssa [7 ]
Dunbar, Nancy M. [8 ]
机构
[1] Cleveland Clin, Robert Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[2] Childrens Natl Med Ctr, Pathol & Lab Med, Washington, DC 20010 USA
[3] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[5] White River Junct VA Med Ctr, Pathol & Lab Med, White River Jct, VT USA
[6] Univ Pittsburgh, Centralized Transfus Serv, Pittsburgh, PA USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Wing Kwai & Alice Lee Tsing Chung Transfus Serv, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[8] Dartmouth Hitchcock Med Ctr, Dept Pathol Lab & Med, Lebanon, NH USA
基金
美国国家卫生研究院;
关键词
PATHOGEN INACTIVATION; REDUCTION; SAFETY;
D O I
10.1111/trf.15693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The United States Food and Drug Administration Final Guidance for Industry titled, "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion" provides nine strategies for platelet bacterial risk mitigation. Even if it is assumed all strategies are comparable in terms of safety and efficacy, the decision of which to implement remains challenging. Some additional factors that warrant evaluation before selecting a strategy include the financial impact, process for implementation, logistics upon implementation, institutional acceptance by blood bank staff, administration and clinicians, and effect on platelet availability. To assist with this difficult choice, a panel of transfusion service physicians who have expertise on the topic and have already selected strategies for their transfusion services were recruited to provide varied perspectives. In addition, the use of a decision-making tool that objectively evaluates defined criteria for assessment of the nine strategies is described.
引用
收藏
页码:675 / 681
页数:7
相关论文
共 2 条
  • [1] A national survey of hospital-based transfusion services on their approaches to platelet bacterial risk mitigation in response to theFDAfinal guidance for industry
    Lu, Wen
    Delaney, Meghan
    Dunbar, Nancy M.
    Rossmann, Susan N.
    Fung, Mark
    TRANSFUSION, 2020, 60 (08) : 1681 - 1687
  • [2] How do we implement Day 6 and Day 7 platelets at a hospital-based transfusion service?
    Dunbar, Nancy M.
    Dumont, Larry J.
    Szczepiorkowski, Zbigniew M.
    TRANSFUSION, 2016, 56 (06) : 1262 - 1266